Mesoblast’s (MESO) “Overweight” Rating Reiterated at Piper Sandler

Piper Sandler reaffirmed their overweight rating on shares of Mesoblast (NASDAQ:MESO) in a report issued on Friday morning,Benzinga reports. Piper Sandler currently has a $24.00 target price on the stock, up from their prior target price of $15.00.

MESO has been the subject of a number of other reports. Cantor Fitzgerald raised Mesoblast to a “strong-buy” rating in a report on Thursday, January 30th. Jefferies Financial Group lowered Mesoblast from a “buy” rating to a “hold” rating in a research note on Monday, December 23rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, two have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.00.

Mesoblast Price Performance

Mesoblast stock opened at $19.49 on Friday. Mesoblast has a one year low of $1.75 and a one year high of $22.00. The business has a fifty day moving average price of $16.48 and a 200-day moving average price of $11.04. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.21.

Institutional Investors Weigh In On Mesoblast

Large investors have recently added to or reduced their stakes in the business. Jane Street Group LLC boosted its stake in Mesoblast by 46.4% during the third quarter. Jane Street Group LLC now owns 85,102 shares of the company’s stock valued at $695,000 after buying an additional 26,959 shares during the period. Clayton Financial Group LLC bought a new stake in Mesoblast during the fourth quarter valued at $275,000. Ballentine Partners LLC purchased a new stake in Mesoblast during the fourth quarter valued at about $222,000. Signaturefd LLC raised its position in Mesoblast by 128.7% during the third quarter. Signaturefd LLC now owns 5,506 shares of the company’s stock valued at $45,000 after purchasing an additional 3,099 shares in the last quarter. Finally, Creative Planning purchased a new stake in Mesoblast during the third quarter valued at about $147,000. Institutional investors own 1.43% of the company’s stock.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.